Sabin Vaccine Institute Receives Additional $34.5 Million from BARDA for Further Development of Ebola Sudan and Marburg Vaccines
21 oct. 2021 09h47 HE
|
The Sabin Vaccine Institute
Washington DC, Oct. 21, 2021 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute (Sabin) announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the...
ContraFect to Present New Late Breaking Phase 2 Exebacase Data on Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia at IDWeek™ 2021
29 sept. 2021 07h30 HE
|
ContraFect Corporation
YONKERS, N.Y., Sept. 29, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection
29 juin 2021 13h58 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
ContraFect Reports First Quarter 2021 Financial Results and Provides Business Update
14 mai 2021 07h30 HE
|
ContraFect Corporation
Interim futility analysis from the Phase 3 DISRUPT study of exebacase evaluating treatment superiority is anticipated in H2 2021 BARDA contract award provides up to $86.8 million for exebacase...
ContraFect Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
30 mars 2021 07h30 HE
|
ContraFect Corporation
Exebacase Phase 3 DISRUPT study enrollment ongoing in patients with Staph aureus bloodstream infections; results from interim futility analysis anticipated in H2 2021 Biomedical Advanced Research...
ContraFect Announces BARDA Contract Award for Up to $86.8 Million and Provides Business Outlook
11 mars 2021 16h05 HE
|
ContraFect Corporation
BARDA to provide funding for the ongoing Phase 3 DISRUPT study of exebacase for the treatment of patients with Staph aureus bloodstream infections Results from the Phase 3 DISRUPT study interim...
PRA Health Sciences selected by BARDA to be a member of its exclusive Clinical Studies Network
06 oct. 2020 16h02 HE
|
PRA Health Sciences, Inc.
With the new contract, PRA will assist Biomedical Advanced Research and Development Authority (BARDA) in the development of medical countermeasures for public health RALEIGH, N.C., Oct. 06, 2020 ...
Cue Health Closes $100 Million Series C Financing to Support Launch of Rapid Molecular Testing Platform
10 juin 2020 09h00 HE
|
Cue Health Inc.
SAN DIEGO, June 10, 2020 (GLOBE NEWSWIRE) -- Cue Health Inc. (“Cue”), a healthcare technology company, announced today the close of its Series C financing round, raising $100 million in new capital....
RenovaCare Appoints Chief Medical Officer, Dr. Jo Ellen Schweinle, Former Sr. Medical Officer at U.S. Dept. of Health and Human Services
10 juin 2020 08h36 HE
|
RenovaCare, Inc.
ROSELAND, N.J., June 10, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration...
RenovaCare Strengthens FDA Program with Leading U.S. Regulatory Group and Significant Investment
28 mai 2020 08h30 HE
|
RenovaCare, Inc.
ROSELAND, N.J., May 28, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration...